Powder: -20°C for 3 years | In solvent: -80°C for 1 year
8-iso-13,14-dihydro-15-keto Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) is a metabolite of the isoprostane, 8-isoprostane (8-iso PGF2α), in rabbits, monkeys and humans. 8-iso PGF2α is a PG-like product of non-specific lipid peroxidation. In both humans and monkeys, exogenously infused 8-isoprostane is converted primarily to metabolites having 2 or 4 carbon atoms removed from the top side chain by β-oxidation. A similar pattern is observed when tritiated 8-isoprostane is infused into rabbits. Early in the infusion (within 10 minutes) 8-iso-13,14-dihydro-15-keto PGF2α was a significant component of the metabolite profile, which was comprised mostly of dinor 8-isoprostane metabolites. 8-iso-13,14-dihydro-15-keto PGF2α weakly inhibits the U-46619 or collagen-induced aggregation of human platelets, although a number of the E-series isoprostanes are much more potent in this assay.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
100 μg | ¥ 2,100 | 35日内发货 | ||
500 μg | ¥ 9,670 | 35日内发货 | ||
1 mg | ¥ 17,900 | 35日内发货 |
产品描述 | 8-iso-13,14-dihydro-15-keto Prostaglandin F2α (8-iso-13,14-dihydro-15-keto PGF2α) is a metabolite of the isoprostane, 8-isoprostane (8-iso PGF2α), in rabbits, monkeys and humans. 8-iso PGF2α is a PG-like product of non-specific lipid peroxidation. In both humans and monkeys, exogenously infused 8-isoprostane is converted primarily to metabolites having 2 or 4 carbon atoms removed from the top side chain by β-oxidation. A similar pattern is observed when tritiated 8-isoprostane is infused into rabbits. Early in the infusion (within 10 minutes) 8-iso-13,14-dihydro-15-keto PGF2α was a significant component of the metabolite profile, which was comprised mostly of dinor 8-isoprostane metabolites. 8-iso-13,14-dihydro-15-keto PGF2α weakly inhibits the U-46619 or collagen-induced aggregation of human platelets, although a number of the E-series isoprostanes are much more potent in this assay. |
别名 | 8-iso-13,14-dihydro-15-keto Prostaglandin F2α |
分子量 | 354.48 |
分子式 | C20H34O5 |
CAS No. | 191919-02-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PBS (pH 7.2): >10 mg/mL (from PGF2a)
10 mM Na2CO3: >6.5 mg/mL (from PGF2a)
Ethanol: >100 mg/mL (from PGF2a)
DMSO: >100 mg/mL (from PGF2a)
DMF: >100 mg/mL (from PGF2a)
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
8-iso-13,14-dihydro-15-keto Prostaglandin F2α 191919-02-5 8 iso 13,14 dihydro 15 keto Prostaglandin F2α 8-iso-13,14-dihydro-15-keto Prostaglandin F-2α 8-iso-13,14-dihydro-15-keto Prostaglandin F2alpha 8iso13,14dihydro15keto Prostaglandin F2α 8-iso-13,14-dihydro-15-keto Prostaglandin F2a Inhibitor inhibitor inhibit